Minerva Neuroscie (NERV) Stock Price, Quote & News

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 600 7373

Website: www.minervaneurosciences.com

Address:

1500 District Avenue, Burlington, United States

ACInvestorBlog Dec. 12 at 6:22 PM

$NERV former runner showing signs of reversal. Daily MACD is triggering a buy signal. If volume comes in, the move could be strong.

0 · Reply

SimpleWinningSetups Dec. 11 at 11:55 PM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $NERV | Timeframe: 3M / 1H Market Cap: $28.53M • Pattern score: 0.73 • Current price: $4.140 • Peak (window): $10.069 • Trough (post-spike): $3.250 • Pullback: ~67.7% from peak • Move off lows: ~41.1% of peak Stock Plan (educational only) • Entry zone: $4.016 – $4.223 • Scalp target: $4.471 → Est. ROI: ~8.0% • Swing target: $6.624 → Est. ROI: ~60.0% • Protective stop: $3.519 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $LULU

0 · Reply

SimpleWinningSetups Dec. 11 at 11:43 PM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $NERV | Timeframe: 6M / 1D Market Cap: $28.53M • Pattern score: 0.66 • Current price: $4.080 • Peak (window): $6.410 • Trough (post-spike): $3.250 • Pullback: ~49.3% from peak • Move off lows: ~63.7% of peak Stock Plan (educational only) • Entry zone: $3.958 – $4.162 • Scalp target: $4.406 → Est. ROI: ~8.0% • Swing target: $5.128 → Est. ROI: ~25.7% • Protective stop: $3.468 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $UNH

0 · Reply

SimpleWinningSetups Dec. 11 at 5:41 AM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $NERV | Timeframe: 3M / 1H Market Cap: $27.34M • Pattern score: 0.71 • Current price: $3.980 • Peak (window): $10.069 • Trough (post-spike): $3.250 • Pullback: ~67.7% from peak • Move off lows: ~39.5% of peak Stock Plan (educational only) • Entry zone: $3.861 – $4.060 • Scalp target: $4.298 → Est. ROI: ~8.0% • Swing target: $6.368 → Est. ROI: ~60.0% • Protective stop: $3.383 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $LDI

0 · Reply

SimpleWinningSetups Dec. 11 at 3:51 AM

0 · Reply

SimpleWinningSetups Dec. 11 at 2:07 AM

0 · Reply

SimpleWinningSetups Dec. 11 at 12:19 AM

0 · Reply

juanagustin2086 Nov. 30 at 6:57 PM

$NERV

0 · Reply

Doozio Nov. 29 at 4:48 PM

Da $NERV to think Roger won’t come rocking 🐒🍌🧠⏰♾️

0 · Reply

ZTradeZone Nov. 28 at 8:57 PM

$NERV psych/CNS biotech with big binary potential, when it jumps it really jumps

0 · Reply

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

Nov 5, 2025, 7:30 AM EST - 5 weeks ago

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Oct 21, 2025, 8:00 AM EDT - 7 weeks ago

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Aug 14, 2025, 4:35 PM EDT - 4 months ago

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

May 13, 2025, 7:30 AM EDT - 7 months ago

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Feb 25, 2025, 7:00 AM EST - 10 months ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Nov 5, 2024, 7:30 AM EST - 1 year ago

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

Feb 27, 2024, 8:14 AM EST - 1 year ago

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Feb 22, 2024, 7:00 AM EST - 1 year ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Nov 7, 2023, 7:30 AM EST - 2 years ago

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Aug 23, 2023, 4:05 AM EDT - 2 years ago

Minerva Neurosciences: There's Probably Time For One More Rally

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Jun 28, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

May 19, 2023, 5:34 PM EDT - 2 years ago

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

May 15, 2023, 11:26 AM EDT - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

May 15, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 10, 2023, 8:00 AM EDT - 2 years ago

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

May 8, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Mar 8, 2023, 11:31 AM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Mar 1, 2023, 8:30 AM EST - 3 years ago

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Nov 9, 2022, 10:02 AM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 8:00 AM EST - 3 years ago

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Nov 2, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Oct 17, 2022, 8:51 AM EDT - 3 years ago

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Oct 17, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Sep 9, 2022, 4:05 PM EDT - 3 years ago

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Aug 22, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

May 4, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Apr 7, 2022, 1:01 PM EDT - 4 years ago

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Apr 7, 2022, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Mar 1, 2022, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Feb 28, 2022, 8:30 AM EST - 4 years ago

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Nov 8, 2021, 2:11 PM EST - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Nov 3, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Nov 1, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Oct 11, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Promotion of Geoff Race to President

Sep 30, 2021, 10:32 AM EDT - 4 years ago

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Sep 30, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Aug 2, 2021, 12:19 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Aug 2, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Jul 26, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Jun 10, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

May 28, 2021, 8:00 AM EDT - 4 years ago

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

May 12, 2021, 4:40 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

May 12, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 11, 2021, 4:15 PM EDT - 4 years ago

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

ACInvestorBlog Dec. 12 at 6:22 PM

$NERV former runner showing signs of reversal. Daily MACD is triggering a buy signal. If volume comes in, the move could be strong.

0 · Reply

SimpleWinningSetups Dec. 11 at 11:55 PM

0 · Reply

SimpleWinningSetups Dec. 11 at 11:43 PM

0 · Reply

SimpleWinningSetups Dec. 11 at 5:41 AM

0 · Reply

SimpleWinningSetups Dec. 11 at 3:51 AM

0 · Reply

SimpleWinningSetups Dec. 11 at 2:07 AM

0 · Reply

SimpleWinningSetups Dec. 11 at 12:19 AM

0 · Reply

juanagustin2086 Nov. 30 at 6:57 PM

$NERV

0 · Reply

Doozio Nov. 29 at 4:48 PM

Da $NERV to think Roger won’t come rocking 🐒🍌🧠⏰♾️

0 · Reply

ZTradeZone Nov. 28 at 8:57 PM

$NERV psych/CNS biotech with big binary potential, when it jumps it really jumps

0 · Reply

Kingcrab3333 Nov. 21 at 12:40 PM

$NERV

0 · Reply

Elaine_Shrimp Nov. 20 at 7:17 AM

$NERV just sit and watch the show😶‍🌫️

0 · Reply

Mg_1970 Nov. 19 at 2:51 PM

$NERV Yesterday Inside Bar ...continuation buy signal at breakout of 4.48-4.5 😎😎👊

0 · Reply

Pbonk Nov. 17 at 6:56 PM

$NERV . Minerva said it raised $80 million upfront through a private financing round backed by LEADING HEALTHCARE INVESTORS.

0 · Reply

Elaine_Shrimp Nov. 17 at 4:13 PM

$NERV avg unit price 4.23. 50K shares LFG .. target to hold for two more weeks.

0 · Reply

Mg_1970 Nov. 17 at 3:15 PM

$CMCT $NERV Halt 😍😍😎

0 · Reply

Simon_Spencer Nov. 14 at 10:24 PM

$NERV Look at the funds in this? there are some quality names, 28% of the float owned by funds, 7% short float, leading group. Look at the 65 min chart, you can see lots of accumulation over the last 9 days, big sell off in the market yesterday and it hardly moved.

0 · Reply

soontobemillion Nov. 14 at 6:57 PM

$NERV CMCT

0 · Reply

Mg_1970 Nov. 14 at 3:03 PM

$CMCT Take an eye at $NERV if it breaks 4.2 with huge volumes 👍😎😎

0 · Reply

Elaine_Shrimp Nov. 14 at 2:58 PM

$NERV now what lol you want to pump dumb dumb??

0 · Reply

S2K_TP Nov. 13 at 2:25 AM

$NERV on watch 👀

0 · Reply

Market Cap	27.12M
Revenue (ttm)	0.00
Net Income (ttm)	1.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	37,300
Avg Vol	3,794,474
Day's Range	N/A - N/A
Shares Out	6.99M
Stochastic %K	68%
Beta	-0.40
Analysts	Hold
Price Target	$4.50